Home > Pulmonology > ERS 2019 > Interstitial Lung Disease > Reduction of FVC decline in systemic sclerosis-associated ILD

Reduction of FVC decline in systemic sclerosis-associated ILD

Presented By
Dr Kristin Highland, Cleveland Clinic, Ohio, USA
ERS 2019
An analysis of the SENSCIS trial showed that the rate of decline in forced vital capacity (FVC) was reduced in patients with systemic sclerosis (SSc)-associated interstitial lung disease (ILD) treated with nintedanib compared with placebo [1]. The large, randomised, controlled SENSCIS trial included 576 patients with SSc who also suffered from ILD with an HRCT scan that showed fibrosis affecting at least 10% of the lungs. Participants had a relatively short course of SSc with a maximum disease duration of 7 years. Participants were assigned to 52 weeks of placebo or 150 mg nintedanib twice weekly in addition to their usual immunosuppressive therapy, which in most cases was mycophenolate mofetil (MMF). “SENSCIS met its primary endpoint: a reduction in the annual rate of decline in FVC,” said Dr Kristin Highland (Cleveland Clinic, Ohio, USA). After a year, in patients who took nintedanib, FVC declined by a mean of 52 mL, which was significantly less t...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on